APA

Comi G., Abramsky O., Arbizu T., Boyko A., Gold R., Havrdová E., Komoly S., Selmaj K., Sharrack B. & Filippi M. (20110215). Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. : Multiple sclerosis (Houndmills, Basingstoke, England).

Chicago

Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B and Filippi M. 20110215. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. : Multiple sclerosis (Houndmills, Basingstoke, England).

Harvard

Comi G., Abramsky O., Arbizu T., Boyko A., Gold R., Havrdová E., Komoly S., Selmaj K., Sharrack B. and Filippi M. (20110215). Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. : Multiple sclerosis (Houndmills, Basingstoke, England).

MLA

Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B and Filippi M. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. : Multiple sclerosis (Houndmills, Basingstoke, England). 20110215.